World’s First Rapid Saliva-Based Pregnancy Test Eliminates Need for Blood and Urine Samples
By LabMedica International staff writers Posted on 09 Dec 2022 |
Saliva contains over 5,000 identified proteins. With significant overlap to blood, saliva is considered the second most important body-fluid for diagnostics. Saliva is a complex fluid which contains markers for several diseases and a variety of hormones. The level of those hormones is significantly lower than in serum/blood or urine. Therefore, only a sensitive test will allow their detection. During pregnancy, the body produces the pregnancy hormone, hCG (human chorionic gonadotropin). A portion of this hormone travels from the blood to the saliva. Levels of hCG continue to increase rapidly during the first three months of pregnancy. Now, a unique pregnancy test that can detect even the low levels of hCG in saliva, could spell the end of traditional tests involving urinating on a stick.
Salistick from Salignostics (Jerusalem, Israel) is the first rapid saliva-based pregnancy test for early and highly accurate pregnancy detection that does not require urine. The kit is based on the company’s revolutionary technology which detects the pregnancy hormone β-hCG in saliva from the first day of the missed period. The amount of this hormone increases as pregnancy progresses. The pregnancy test kit contains a sealed pouch with a collection handle, analytical unit and a preservative silica bag (to be tossed away), along with instructions for use.
The collection foam absorbs saliva from the mouth. When the user connects the collection handle to the analytical unit, the saliva is squeezed and migrates along a special membrane until it reaches the test zone. In the presence of the hCG pregnancy hormone, a pink line appears. The absence of this test line suggests a negative result. A pink control line appears if the test was performed properly. The test can be easily performed at home at any time of the day (30 minutes after drinking or eating). In laboratory testing with saliva samples of pregnant women from the first day after their missed period, SaliStick test gave 95% positive results. SaliStick is expected to be available for purchase in several European countries, as well as South Africa, UAE, and Israel from the first quarter of 2023. Salignostics is also developing other tests, including kits for detection of malaria, cardiac risk and H. pylori bacteria.
Related Links:
Salignostics
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer